PharMerica Corp. (NYSE:PMC) rose 3.6% during trading on Friday . The stock traded as high as $22.12 and last traded at $22.09, with a volume of 307,633 shares trading hands. The stock had previously closed at $21.32.

PMC has been the topic of several research reports. Zacks Investment Research cut PharMerica Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday. TheStreet cut PharMerica Corp. from a “buy” rating to a “hold” rating in a research note on Monday, May 9th. Barrington Research restated an “outperform” rating and issued a $34.00 target price (up previously from $30.00) on shares of PharMerica Corp. in a research note on Tuesday, May 10th. Finally, Bank of America Corp. initiated coverage on PharMerica Corp. in a research note on Tuesday, June 7th. They issued a “buy” rating and a $32.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $31.57.

The stock has a 50 day moving average price of $25.12 and a 200 day moving average price of $24.74. The company has a market cap of $678.96 million and a P/E ratio of 22.80.

PharMerica Corp. (NYSE:PMC) last released its earnings results on Tuesday, August 9th. The company reported $0.47 EPS for the quarter, hitting the consensus estimate of $0.47. The business had revenue of $519.60 million for the quarter, compared to analyst estimates of $508.31 million. During the same period in the prior year, the business earned $0.48 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts forecast that PharMerica Corp. will post $2.01 earnings per share for the current year.

A number of large investors have added to or reduced their stakes in PMC. Wells Fargo & Company MN boosted its stake in PharMerica Corp. by 3.6% in the fourth quarter. Wells Fargo & Company MN now owns 305,474 shares of the company’s stock valued at $10,692,000 after buying an additional 10,609 shares in the last quarter. California Public Employees Retirement System boosted its stake in PharMerica Corp. by 3.8% in the fourth quarter. California Public Employees Retirement System now owns 111,808 shares of the company’s stock valued at $3,913,000 after buying an additional 4,100 shares in the last quarter. Airain ltd boosted its stake in PharMerica Corp. by 8,998.1% in the fourth quarter. Airain ltd now owns 1,222,061 shares of the company’s stock valued at $14,499,000 after buying an additional 1,208,629 shares in the last quarter. Trexquant Investment LP boosted its stake in PharMerica Corp. by 148.9% in the fourth quarter. Trexquant Investment LP now owns 30,140 shares of the company’s stock valued at $1,055,000 after buying an additional 18,031 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in PharMerica Corp. by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,579,111 shares of the company’s stock valued at $90,269,000 after buying an additional 41,387 shares in the last quarter.

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.